Schechter Investment Advisors LLC Has $1.15 Million Holdings in ICON Public Limited (NASDAQ:ICLR)

Schechter Investment Advisors LLC lessened its stake in ICON Public Limited (NASDAQ:ICLR) by 9.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,048 shares of the medical research company’s stock after selling 440 shares during the quarter. Schechter Investment Advisors LLC’s holdings in ICON Public were worth $1,146,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. First Horizon Advisors Inc. grew its position in ICON Public by 10.9% in the first quarter. First Horizon Advisors Inc. now owns 551 shares of the medical research company’s stock worth $118,000 after acquiring an additional 54 shares in the last quarter. Laurel Wealth Advisors Inc. grew its position in ICON Public by 2.0% in the first quarter. Laurel Wealth Advisors Inc. now owns 2,708 shares of the medical research company’s stock worth $658,000 after acquiring an additional 54 shares in the last quarter. Steph & Co. grew its position in ICON Public by 4.6% in the third quarter. Steph & Co. now owns 1,670 shares of the medical research company’s stock worth $411,000 after acquiring an additional 73 shares in the last quarter. Farther Finance Advisors LLC grew its position in ICON Public by 102.7% in the second quarter. Farther Finance Advisors LLC now owns 150 shares of the medical research company’s stock worth $38,000 after acquiring an additional 76 shares in the last quarter. Finally, Bruce G. Allen Investments LLC bought a new stake in ICON Public in the fourth quarter worth approximately $25,000. Institutional investors and hedge funds own 95.61% of the company’s stock.

ICON Public Trading Down 0.1 %

Shares of ICLR stock opened at $329.50 on Thursday. ICON Public Limited has a 52-week low of $181.92 and a 52-week high of $344.77. The stock has a market cap of $27.18 billion, a price-to-earnings ratio of 44.65, a P/E/G ratio of 1.54 and a beta of 1.15. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.21 and a current ratio of 1.21. The firm has a fifty day moving average of $300.71 and a 200-day moving average of $273.83.

ICON Public (NASDAQ:ICLR) last announced its earnings results on Wednesday, February 21st. The medical research company reported $3.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.27 by $0.13. The business had revenue of $2.07 billion during the quarter, compared to analysts’ expectations of $2.08 billion. ICON Public had a net margin of 7.54% and a return on equity of 11.42%. On average, equities research analysts forecast that ICON Public Limited will post 14.4 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on ICLR shares. Evercore ISI boosted their target price on shares of ICON Public from $325.00 to $350.00 and gave the stock an “outperform” rating in a research report on Friday, February 23rd. Barclays upped their price objective on shares of ICON Public from $325.00 to $355.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. Citigroup upped their price objective on shares of ICON Public from $300.00 to $315.00 and gave the stock a “buy” rating in a report on Monday, December 11th. JPMorgan Chase & Co. upped their price objective on shares of ICON Public from $295.00 to $330.00 and gave the stock an “overweight” rating in a report on Wednesday, December 20th. Finally, Mizuho upped their target price on shares of ICON Public from $315.00 to $346.00 and gave the company a “buy” rating in a research note on Friday, February 23rd. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, ICON Public presently has a consensus rating of “Moderate Buy” and an average target price of $312.64.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.